Lispro insulin: Benefits and limitations

Trends in Endocrinology and Metabolism

Volumn 9, Issue 8, 1998, Pages 337-341

  Burge, Mark R ^a   Rassam, Amer G ^a   Schade, David S ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN RECEPTOR; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031706975     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00083-6     Document Type: Review

References (23)

1. Ahmed ABE, Home PD The effect of the insulin analog Lispro insulin on nighttime blood glucose control in type 1 diabetic patients. Diabetes Care. 21:1998;32-37.
2. Anderson JH, Brunelle RL, Keohane Pet al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 157:1997;1249-1255.
3. Anderson JH, Brunelle RL, Koivisto VAet al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 46:1997;265-270.
4. Braak EW, Woodworth JR, Bianchi Ret al. Injection site effects on the pharmacokinetics and glucodynamics of insulin Lispro and regular insulin. Diabetes Care. 19:1996;1437-1440.
5. Brange J, Owens DR, Kang S, Volund A Monomeric insulins and their experimental and clinical implications. Diabetes Care. 13:1990;923-954.
6. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes. 37:1988;736-744.
7. Burge MR, Schade DS Insulins. Endocrinol Metab Clin North Am. 26:1997;575-598.
8. Burge MR, Castillo KR, Schade DS Meal composition is a determinant of insulin Lispro induced hypoglycemia in IDDM. Diabetes Care. 20:1997;152-155.
9. Burge MR, Waters DL, Holcombe JH, Schade DS Prolonged efficacy of short-acting insulin Lispro in combination with human Ultralente in IDDM. J Clin Endocrinol Metab. 82:1997;920-924.
10. Dimitriadis GD, Gerich JE Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 6:1983;374-377.
11. Drejer K The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev. 8:1992;259-286.
12. Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA Strategies toward improved control during insulin Lispro therapy in IDDM: importance of basal insulin. Diabetes Care. 20:1997;1287-1289.
13. Fineberg NS, Fineberg SE, Anderson JHet al. Immunologic effects of insulin Lispro [Lys(B28),Pro(B29)] in IDDM and NIDDM patients previously treated with insulin. Diabetes. 45:1996;1750-1754.
14. Heinemann L, Starke AA, Hohmann A, Berger M Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res. 26(Supp):1992;137-139.
15. Holleman F, Hoekstra JB Insulin lispro. New Engl J Med. 337:1997;176-183.
16. Holleman F, Schmitt H, Rottiers Ret al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin Lispro. Diabetes Care. 20:1997;1827-1832.
17. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 43:1994;396-402.
18. Lougheed WD, Zinman B, Strack Tet al. Stability of insulin Lispro in insulin infusion systems. Diabetes Care. 20:1997;1061-1065.
19. Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA Postprandial insulin Lispro: a new therapeutic option for type 1 diabetic patients. Diabetes Care. 4:1998;570.
20. Slieker LJ, Broke GS, Chance RE Insulin and IGF-1 analogs: novel approaches to improved insulin pharmacokinetics. Adv Exp Med Biol. 343:1993;25-32.
21. Torlone E, Fanelli C, Rambotti AMet al. Pharmacokinetics, pharmacodynamics and glucose counter regulation following subcutaneous injection of the monomeric insulin analog[Lys(B28),Pro(B29)] in IDDM. Diabetologia. 37:1994;713-720.
22. Van Haeften TW, Krom BA, Gerich JE Prolonged fasting hypoglycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus: effect of insulin withdrawal on insulin-antibody-binding kinetics. Diabetes Care. 10:1987;160-163.
23. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T Insulin Lispro in CSII: results of a double-blind crossover study. Diabetes. 46:1997;440-443.